MeiraGTx Holdings plc Liquidation Value

MGTX Biotechnology

Cash & Equivalents

$65.93M
As of 2025-12-31
Current Price: N/A

Key Metrics

Cash Liquidation Value

Cash minus Total Obligations
Cash: $65.93M
Total Obligations: -$134.01M
$-68.08M
Per share: $-0.84
Period: 2025-12-31
incomplete 1 component missing — treated as $0 in formula. Why?
  • Long-Term Debt: not reported

Liquid Liquidation Value

Cash + AR minus Total Obligations
Cash: $65.93M
AR: $3.00M
Total Obligations: -$134.01M
$-65.08M
Per share: $-0.80
Period: 2025-12-31
incomplete 1 component missing — treated as $0 in formula. Why?
  • Long-Term Debt: not reported

Operating Liquidation Value

Cash + AR + Inventory minus Total Obligations
Cash: $65.93M
AR: $3.00M
Inventory: N/A
Total Obligations: -$134.01M
$-65.08M
Per share: $-0.80
Period: 2025-12-31
incomplete 2 components missing — treated as $0 in formula. Why?
  • Inventory: not reported in this period (annual-only)
  • Long-Term Debt: not reported

Build your own liquidation scenario

Adjust asset discounts and liability assumptions to see how assumptions affect the numbers.

Open Calculator →

Liquidation Ladder

MetricTotalPer Share
Cash Liquidation Value$-68.08M$-0.84
Liquid Liquidation Value$-65.08M$-0.80
Operating Liquidation Value$-65.08M$-0.80

Key Components (as of 2025-12-31)

Data as of 2025-12-31 from 10-K filed 2026-03-30. View on SEC EDGAR →

Cash & Equivalents$65.93M
Accounts Receivable$3.00M
InventoryN/A
Current Liabilities$122.56M
Long-term DebtN/A
Op. Lease Liability$11.35M
Finance Lease$109,000
Shares Outstanding81.1M

Explore all 191 XBRL tags and build your own scenario → Open Calculator

Historical

PeriodCashARInventoryAPCurr LiabLT DebtOp LeaseFin Lease
2025-12-31$65.93M$3.00MN/A$10.07M$122.56MN/A$11.35M$109,000
2025-09-30$14.84M$2.81MN/A$21.54M$152.92MN/A$11.53MN/A
2025-06-30$32.17M$2.32M$314,000$25.59M$53.44MN/A$4.05MN/A
2025-03-31$66.52M$734,000$607,000$20.29M$52.37MN/A$4.09MN/A

Comments

SEC Filings

PeriodFormFiledLink
2025-12-31 10-K 2026-03-30 View
2025-09-30 10-Q 2025-11-13 View
2025-06-30 10-Q 2025-08-14 View
2025-03-31 10-Q 2025-05-13 View
2024-12-31 10-K 2025-03-13 View
2024-09-30 10-Q 2024-11-13 View
2024-06-30 10-Q 2024-08-12 View
2024-03-31 10-Q 2024-05-09 View

AI Insights

AI Insight·Generated 2026-05-05

MeiraGTx Holdings plc (MGTX) presents a deeply negative liquidation posture as of December 31, 2025. MFFAIS-derived CLV is negative $68.1M, consistent with the balance-sheet arithmetic: total liabilities of $250.2M exceed total assets of $244.4M, producing book equity of negative $5.8M before applying recovery haircuts. Under liquidation-lens haircuts, the deficit widens materially. Cash and restricted cash of $68.2M recovers at par. Accounts receivable of $3.0M recovers at ~90-95% ($2.7-2.9M). The dominant non-cash asset class is net PP&E of $105.5M (gross $158.1M less $52.6M accumulated depreciation), which at a 50-70% haircut recovers $52.7-73.8M, not $105.5M. Finance lease ROU asset of $23.6M and operating lease ROU asset of $12.9M carry zero liquidation value as they represent contracted use rights, not transferable assets. Intangibles of $0.6M carry zero recovery. The liability stack is carried at face value: current liabilities total $122.6M, dominated by a $50.3M OtherLiabilitiesCurrent line (which the filing context indicates is substantially deferred revenue related to the Eli Lilly collaboration recognized in Q4 2025), $32.9M AccruedLiabilitiesCurrent, $24.6M NotesPayableCurrent (Perceptive credit facility current portion), and $10.1M AccountsPayableCurrent. Non-current liabilities include $49.7M LongTermNotesPayable (Perceptive notes, net of discount), $65.1M DeferredIncomeNoncurrent (remaining Lilly deferred revenue), and $14.2M total operating lease liability. The Perceptive credit facility is reflected in both current and non-current debt tranches totaling approximately $74.3M face across both lines. A post-period Amendment No. 4 to the Notes Purchase Agreement (Exhibit 10.53, dated March 25, 2026) modifies warrant certificates, signaling ongoing negotiation with the senior secured lender. The Lilly collaboration (Exhibit 10.52, November 2025) generated substantial upfront deferred revenue now sitting as a face-value liability. The filing does not separately XBRL-tag the Lilly upfront payment amount or the Perceptive total face-value debt in a single tag; both are discussed in MD&A but component detail is spread across multiple balance-sheet lines. Accumulated deficit stands at $816.2M. Net loss for 2025 was $114.2M on revenues of $81.4M, with operating cash outflow of $46.4M. Cash decreased by $38.2M during the year. The company had ~$65.9M unrestricted cash at year-end, providing near-term runway but insufficient to retire senior secured debt at face value. Recovery to equity in a wind-down scenario is negative after settling senior secured notes, lease obligations, and accrued liabilities at face.

Flags

Loading flags...

AI Insight Discussion

Loading...

Community Notes

Loading notes...

Questions

Loading questions...